Baird analyst Catherine Ramsey Schulte lowered the firm’s price target on Twist Bioscience (TWST) to $44 from $54 and keeps an Outperform rating on the shares. The firm updated its model following Q2 results.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TWST:
- Cautious Outlook on Twist Bioscience Amidst Macroeconomic Challenges and Premium Valuation
- Twist Bioscience price target lowered to $33 from $40 at JPMorgan
- Twist Bioscience Reports Record Revenue and Strategic Spin-Out
- Twist Bioscience’s Earnings Call Highlights Record Growth
- Morning Movers: Skechers surges following take-private deal
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue